Phase I, single-center, non-randomized study of nifedipine GITS/candesartan fixed-dose combination in patients with hepatic impairment

Trial Profile

Phase I, single-center, non-randomized study of nifedipine GITS/candesartan fixed-dose combination in patients with hepatic impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Candesartan cilexetil/nifedipine (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Jan 2017 New trial record
    • 27 Dec 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top